[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100314066":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":31,"responsibleParty":48,"collaborators":18,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":18,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":18,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":18,"overallStatus":34,"whyStopped":18,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"treatment group","EXPERIMENTAL","transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)",[13],"Procedure: TAI",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","NO_INTERVENTION","no neo-adjuvant treatment before operation",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"PROCEDURE","TAI","transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Shaohua Li, MD","CONTACT","+8615088064187","lishaoh@sysucc.org.cn",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Cancer Center of Sun Yat-Sen University","RECRUITING","Guangzhou","Guangdong","+86","China","CN",{"type":41,"coordinates":42},"Point",[43,44],113.25,23.11667,{"lat":44,"lon":43},[47],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Rong-ping Guo","Professor","100314066","phase-3-the-impact-on-survival-of-neo-adjuvant-transarterial-chemoinfusion-tai-for-patients-with-hepatocellular-carcinoma-and-portal-vein-tumor-thrombosis-pvtt-who-underwent-hepatectomy--a-random-controlled-stage-iii-clinical-trial-100314066",false,"NCT03368651","The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.","Inclusion Criteria:\n\n* older than 18 years old and younger than 75 years;\n* ECOG PS≤1;\n* proven hepatocellular carcinoma according patological examination or EASL\u002FAASLD diagnostic criteria;\n* not previous treated for tumor;\n* estimated tumor and tumor thrombosis could be removed en bloc in operation;\n* no distant metastasis;\n* the lab test could meet: neutrophil count≥2.0×109\u002FL; hemoglobin≥100g\u002FL; platelet count≥75×109\u002FL; serum albumin≥35g\u002FL; total bilirubin\\\u003C2-times upper limit of normal; ALT\\\u003C3-times upper limit of normal; AST\\\u003C3-times upper limit of normal; serum creatine\\\u003C1.5-times upper limit of normal; PT≤upper limit of normal plus 4 seconds; INR≤2.2;\n* sign up consent;\n\nExclusion Criteria:\n\n* cannot tolerate TAI or surgery;\n* distant metastasis exits;\n* known history of other malignancy;\n* be allergic to related drugs;\n* underwent organ transplantation before;\n* be treated before (interferon included);\n* known history of HIV infection;\n* known history of drug or alcohol abuse;\n* have GI hemorrhage or cardiac\u002Fbrain vascular events within 30 days;\n* pregnancy;","ALL","18 Years","75 Years",{"count":62,"type":63},230,"ESTIMATED","INTERVENTIONAL",[66],"PHASE3","To compare the impact on survival of neo-adjuvant TAI for patients with HCC and PVTT who underwent hepatectomy.",[69],"Hepatocellular Carcinoma","2017-12-08",{"date":72,"type":73},"2017-12-11","ACTUAL",{"date":75,"type":73},"2016-01-01",{"date":77,"type":63},"2028-12-31",{"name":5,"class":6},1]